CLINICAL RESEARCH
Frequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes
L. Kristin Newby, MD, MHS, FACC*,*,
Matthew T. Roe, MD, MHS, FACC*,
Anita Y. Chen, MS*,
E. Magnus Ohman, MD, FACC ,
Robert H. Christenson, PhD ,
Charles V. Pollack, Jr, MD, MA ,
James W. Hoekstra, MD||,
W. Frank Peacock, MD¶,
Robert A. Harrington, MD, FACC*,
Robert L. Jesse, MD, PhD, FACC**,
W. Brian Gibler, MD,
Eric D. Peterson, MD, MPH, FACC* the CRUSADE Investigators
*Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
Division of Cardiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina
Department of Pathology, University of Maryland, Baltimore, Maryland
Department of Emergency Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania
|| Department of Emergency Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina
¶ Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
** Division of Cardiology, Medical College of Virginia and Veterans Administration Medical Center, Richmond, Virginia
Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio
Manuscript received May 18, 2005;
revised manuscript received July 24, 2005,
accepted August 1, 2005.
* Reprint requests and correspondence: Dr. L. Kristin Newby, Duke Clinical Research Institute, P.O. Box 17969, Durham, North Carolina 27715-7969
(Email: newby001{at}mc.duke.edu).
OBJECTIVES: We sought to evaluate the association between discordant cardiac marker results and in-hospital mortality and treatment patterns in patients with non–ST-segment elevation acute coronary syndromes (NSTE ACS).
BACKGROUND: Creatine kinase-MB (CK-MB) and cardiac troponins (cTn) are often measured concurrently in patients with NSTE ACS. The significance of discordant CK-MB and cTn results is unknown.
METHODS: Among 29,357 ACS patients in the CRUSADE initiative who had both CK-MB and cTn measured during the first 36 hours, we examined relationships of four marker combinations (CK-MB–/cTn–, CK-MB+/cTn–, CK-MB–/cTn+, and CK-MB+/cTn+) with mortality and American College of Cardiology/American Heart Association guidelines-recommended acute care.
RESULTS: The CK-MB and cTn results were discordant in 28% of patients (CK-MB+/cTn–, 10%; CK-MB–/cTn+, 18%). In-hospital mortality was 2.7% among CK-MB–/cTn– patients; 3.0%, CK-MB+/cTn–; 4.5%, CK-MB–/cTn+; and 5.9%, CK-MB+/cTn+. After adjustment for other presenting risk factors, patients with CK-MB+/cTn– had a mortality odds ratio (OR) of 1.02 (95% confidence interval [CI] 0.75 to 1.38), those with CK-MB–/cTn+ had an OR of 1.15 (95% CI 0.86 to 1.54), and those with CK-MB+/cTn+ had an OR of 1.53 (95% CI 1.18 to 1.98). Despite variable risk, patients with CK-MB+/cTn– and CK-MB–/cTn+ were treated similarly with early antithrombotic agents and catheter-based interventions.
CONCLUSIONS: Among patients with NSTE ACS, an elevated troponin level identifies patients at increased acute risk regardless of CK-MB status, but an isolated CK-MB+ status has limited prognostic value. Recognition of these risk differences may contribute to more appropriate early use of antithrombotic therapy and invasive management for all cTn+ patients.
|
Abbreviations and Acronyms
| | ACC = American College of Cardiology/ | | ACS = acute coronary syndrome | | AHA = American Heart Association | | CI = confidence interval | | CK-MB = creatine kinase-MB | | CRUSADE = Can Rapid Risk stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines | | cTn = cardiac troponin | | NSTE = non–ST-segment elevation | | OR = odds ratio | | ULN = upper limit of normal |
|
This article has been cited by other articles:
|
|
|
|
 
E. J. van den Bos, A. A. Constantinescu, R. T. van Domburg, S. Akin, L. J. Jordaens, and M. J. M. Kofflard
Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation
Eur. Heart J.,
March 1, 2011;
32(5):
611 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Lansky and G. W. Stone
Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention
Circ Cardiovasc Interv,
December 1, 2010;
3(6):
602 - 610.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels, G. A. Laughlin, P. Clopton, A. S. Maisel, and E. Barrett-Connor
Minimally Elevated Cardiac Troponin T and Elevated N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality in Older Adults: Results From the Rancho Bernardo Study
J. Am. Coll. Cardiol.,
August 5, 2008;
52(6):
450 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bagwe, R. Sachdeva, and J. L. Mehta
High-risk acute coronary syndrome patient and cardiac biomarkers in the emergency department: where do we stand?
Eur. Heart J.,
May 1, 2007;
28(9):
1043 - 1044.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl and R. Charnigo
Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough
JAMA,
April 5, 2006;
295(13):
1581 - 1582.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Post Hoc Analysis of Cardiac Marker Data from the CRUSADE Study
Journal Watch Emergency Medicine,
March 28, 2006;
2006(328):
13 - 13.
[Full Text]
|
|
|
|
